TL1A–DR3 Signaling and Experimental Crohn’s Disease

The TL1A–DR3 signaling pathway plays a central role in the development and progression of Crohn’s disease (CD), a chronic inflammatory condition of the intestines. Research has shown that TL1A activates DR3, a receptor that drives proinflammatory immune responses, particularly through T helper 9 (Th9) cells. These Th9 cells produce interleukin-9 (IL-9), a key inflammatory cytokine that contributes to intestinal damage and inflammation in CD.

Using experimental models, researchers studied mice with Crohn’s-like ileitis (SAMP1/YitFc) and DR3-deficient mice to understand the role of this pathway. DR3-deficient mice exhibited reduced intestinal inflammation, lower IL-9 levels, and improved histology, highlighting DR3’s role in sustaining immune hyperactivation. Neutralizing IL-9 with antibodies significantly alleviated inflammation and tissue damage, confirming IL-9’s importance in disease progression.

Under Th9-polarizing conditions, DR3 was essential for inducing IL-9 production. Wild-type Th9 cells (Th9^WT) showed high levels of IL-9 and other inflammatory cytokines, while DR3-deficient Th9 cells (Th9^KO) shifted toward an anti-inflammatory phenotype, producing more IL-10. Molecular studies revealed that DR3 deficiency suppressed proinflammatory genes and pathways, including JAK/STAT and PI3K–AKT, while enhancing regulatory markers like Foxp3 and IL-10.

Human studies validated these findings, showing upregulation of Th9-related genes in Crohn’s disease patients, linking the TL1A–DR3–IL-9 axis to human intestinal inflammation. Therapeutically, targeting DR3 or IL-9 could provide a novel approach to treat Crohn’s disease by reducing Th9-driven inflammation and restoring immune balance.